Optimizing Management to Reduce the Mortality of COVID-19: Experience From a Designated Hospital for Severely and Critically Ill Patients in China
Wei Zhu(Shanghai Tenth People's Hospital), Jihong Liu(Tongji Hospital), Huan Feng(Tongji Hospital), Jianping Zhao(Xinjiang University), Ganxun Li(Tongji Hospital), Zhouping Tang(Huazhong University of Science and Technology), Gang Xu(University of Michigan), Ning Zhou(Tongji Hospital), Huaqiu Zhang(Tongji Hospital), Yajun Ruan(Tongji Hospital), Zeyang Ding(Huazhong University of Science and Technology), Bixiang Zhang(Ministry of Education of the People's Republic of China), Zhuo Liu(Peking University), Hui Wang(Weifang Medical University), Bo Liu(Union Hospital), Yong Li(Huazhong University of Science and Technology), Jiangang Jiang(Tongji Hospital), Dao Wen Wang(Tongji Hospital), Zhixiang Wen(Tongji Hospital), Fan He(Jiangnan University)
Cited by 10
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
|Journal of Allergy and Clinical Immunology|2020|2.4k
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.8k
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
|Chinese Medical Journal|2020|1.4k